KRIBIOLISA™ Anti-Infliximab (REMICADE) ELISA
Enzyme Immunoassay for the quantitative determination of Anti-Infliximab antibodies in human serum and plasma.
Receive your quote directly from the manufacturer.
Anti-Infliximab ELISA for screening of antibodies to Infliximab in serum and plasma.
Intended Use:
The KRIBIOLISA™ Anti-Infliximab ELISA is used as an analytical tool for quantitative determination of Anti-
Infliximab in serum, plasma and cell culture supernatant.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Infliximab is pre-coated onto microwells. Samples and standards are pipetted into microwells and antibodies to Infliximab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated Infliximab is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the
amount of Anti-Infliximab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
- Calibrator Range: 0 ng/ml - 480 ng/ml
- Sensitivity: 50 ng/ml
- Sample Type: serum, plasma and cell culture supernatant
- Shipping Condition: 2 - 8 Deg C
- Detection Method: Colorimetric
- Usage: For In-Vitro Diagnostic Use Only
- Research Area: Therapeutic Drug Monitoring
